Compare CRTO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | ZLAB |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | France | China |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 2.6B |
| IPO Year | 2013 | 2017 |
| Metric | CRTO | ZLAB |
|---|---|---|
| Price | $17.14 | $24.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $34.00 | ★ $49.60 |
| AVG Volume (30 Days) | 321.5K | ★ 942.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | 38.46 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,296,692,000.00 | $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $5.54 | $26.03 |
| P/E Ratio | $47.14 | ★ N/A |
| Revenue Growth | ★ 27.65 | 15.33 |
| 52 Week Low | $15.58 | $15.96 |
| 52 Week High | $25.29 | $34.72 |
| Indicator | CRTO | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 50.08 |
| Support Level | $16.57 | $16.84 |
| Resistance Level | $18.24 | $25.28 |
| Average True Range (ATR) | 0.56 | 0.81 |
| MACD | 0.08 | -0.45 |
| Stochastic Oscillator | 29.27 | 24.35 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.